<DOC>
	<DOCNO>NCT00375219</DOCNO>
	<brief_summary>To evaluate safety efficacy subcutaneous administration omacetaxine mepesuccinate ( HHT ) achieve clinical response CML patient chronic , accelerate , blast phase fail prior imatinib therapy T315I kinase domain gene mutation .</brief_summary>
	<brief_title>Homoharringtonine ( Omacetaxine Mepesuccinate ) Treating Patients With Chronic Myeloid Leukemia ( CML ) With T315I BCR-ABL Gene Mutation</brief_title>
	<detailed_description>Point mutation within ABL kinase domain BCR-ABL gene emerge frequent mechanism resistance imatinib resultant reactivation kinase activity . The risk mutation development particularly high patient beyond chronic phase , well long duration disease prior imatinib therapy . The T315I kinase domain ( KD ) point mutation merit particular attention , T315I express CML cell markedly resistant imatinib . CML patient T315I KD mutation , therefore , respond continue treatment imatinib , preliminary clinical data indicate neither two new tyrosine kinase inhibitor activity patient T315I KD mutation either . Omacetaxine mepesuccinate ( HHT ) potent inducer apoptosis ( program cell death ) myeloid cell inhibit angiogenesis ( blood vessel formation ) . In Phase 2 study , HHT demonstrate clinical activity patient CML , single agent in-combination chemotherapeutic drug . HHT work via different mechanism imatinib tyrosine kinase inhibitor ( TKI 's ) , HHT show inhibit vitro CML cell line harbor T315I KD mutation highly resistant imatinib . Therefore , CML patient T315I KD mutation may still respond treatment HHT . HHT may therefore attractive therapeutic option patient T315I KD mutation . On basis , multicenter clinical trial conduct HHT therapy CML patient fail prior imatinib therapy T315I KD mutation . Patients treated induction course consist subcutaneous ( SC ) HHT twice daily 14 consecutive day every 28 day . Patients demonstrate response , may receive maintenance therapy 24 month , consist subcutaneous ( SC ) HHT twice daily 7 day every 28 day .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Homoharringtonine</mesh_term>
	<mesh_term>Harringtonines</mesh_term>
	<criteria>Male female patient , age 18 year old Philadelphia chromosome ( Ph ) positive chronic myelogenous leukemia either chronic , accelerate , blast phase The patient T315I BCRABL gene mutation Patients fail prior imatinib therapy ECOG performance status 02 NYHA class III IV heart disease , active ischemia uncontrolled cardiac condition angina pectoris , clinically significant cardiac arrhythmia require therapy , uncontrolled hypertension congestive heart failure Myocardial infarction previous 12 week Lymphoid Ph+ blast crisis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Chronic Myeloid Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>HHT</keyword>
	<keyword>Homoharringtonine</keyword>
	<keyword>Omacetaxine</keyword>
	<keyword>T315i</keyword>
	<keyword>ChemGenex</keyword>
	<keyword>ChemGenex Pharmaceuticals</keyword>
</DOC>